Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
March 21, 2023 06:30 ET
|
Mereo BioPharma Group plc
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional...
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 08, 2023 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 08, 2022 07:00 ET
|
Mereo BioPharma Group plc
LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
November 02, 2022 16:01 ET
|
Mereo BioPharma Group plc
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
October 28, 2022 07:00 ET
|
Mereo BioPharma Group plc
Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024...
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
October 24, 2022 16:30 ET
|
Mereo BioPharma Group plc
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
October 21, 2022 07:00 ET
|
Mereo BioPharma Group plc
Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s...
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
October 18, 2022 07:00 ET
|
Mereo BioPharma Group plc
Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones Reiterates Commitment to Disciplined...
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
October 17, 2022 07:00 ET
|
Mereo BioPharma Group plc
Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 ...
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
October 03, 2022 17:00 ET
|
Mereo BioPharma Group plc
Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced,...